Plasma Renin Activity Testing to Guide Triple Antirenin System Drug Therapy in a Patient With Difficult-to-Treat Hypertension

Annals of Pharmacotherapy

Volumn 48, Issue 2, 2014, Pages 279-285

  Shah, Sachil ^a   Coakley, Christina ^b   Hough, Augustus ^b   Parra, David ^b,c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

hypertension; pharmacotherapy; plasma renin activity; renin; treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALISKIREN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CHLORTALIDONE; CYANOCOBALAMIN; DILTIAZEM; FOLIC ACID; IBUPROFEN; LISINOPRIL; MORPHINE SULFATE; OMEPRAZOLE; OXYCODONE; POTASSIUM CHLORIDE; PRAVASTATIN; RENIN; THIAMINE; VALSARTAN;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BEDTIME DOSAGE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CASE REPORT; CLINICAL FEATURE; COUGHING; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FATIGUE; FOOT EDEMA; HUMAN; HYPERTENSION; MALE; MORNING DOSAGE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

HYPERTENSION; PHARMACOTHERAPY; PLASMA RENIN ACTIVITY; RENIN; TREATMENT;

AGED; AMIDES; ANTIHYPERTENSIVE AGENTS; CARBAZOLES; FUMARATES; HUMANS; HYPERTENSION; MALE; PROPANOLAMINES; RENIN; TETRAZOLES; VALINE;

EID: 84893318035     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013512788     Document Type: Article

References (28)

1. Chobanian AV,Bakris GL,Black HR,et al.Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.Hypertension. 2003;4:1206-1252.
2. Daugherty SL,Powers JD,Magid DJ,et al.Incidence and prognosis of resistant hypertension in hypertensive patients.Circulation. 2012;125:1635-1642.
3. Yoon SS,Burt V,Louis T,Carroll MDHypertension Among Adults in the United States, 2009-2010. Hyattsville, MD: National Center for Health Statistics; 2012:.
4. Calhoun DA,Jones D,Textor S,et al.Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.Hypertension. 2008;51:1403-1419.
5. Cushman WC,Ford CE,Cutler JA,et al.Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).J Clin Hypertens (Greenwich). 2002;4:393-404.
6. Calhoun DA,Jones D,Textor S,et al.Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.Hypertension. 2008;51:1403-1419.
7. Ferrario CM,Flack JM,Strobeck JE,Smits G,Peters C.Individualizing hypertension treatment with impedance cardiography: a meta-analysis of published trials.Ther Adv Cardiovasc Dis. 2010;4:5-16.
8. Olson N,DeJongh B,Hough A,Parra D.Plasma renin activity-guided strategy for the management of hypertension.Pharmacotherapy. 2012;32:446-455.
9. Laragh J.Laragh's lessons in pathophysiology and clinical pearls for treating hypertension.Am J Hypertens. 2001;14:186-194.
10. Laragh JH.Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles.Am J Med. 1973;55:261-274.
11. Laragh J.Laragh's lessons in pathophysiology and clinical pearls for treating hypertension.Am J Hypertens. 2001;14:733-742.
12. Laragh J.Laragh's lessons in pathophysiology and clinical pearls for treating hypertension.Am J Hypertens. 2001;14:491-503.
13. Turner ST,Schwartz GL,Chapman AB,et al.Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension.Am J Hypertens. 2010;23:1014-1022.
14. Preston RA,Materson BJ,Reda DJ,et al.Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. department of veterans affairs cooperative study group on antihypertensive agents.JAMA. 1998;280:1168-1172.
15. Dickerson JE,Hingorani AD,Ashby MJ,Palmer CR,Brown MJ.Optimisation of antihypertensive treatment by crossover rotation of four major classes.Lancet. 1999;353:2008-2013.
16. Schwartz GL,Bailey K,Chapman AB,Berowinkle E,Turner ST.The role of plasma renin activity, age, and race in selecting effective initial drug therapy for hypertension.Am J Hypertens. 2013;26:957-964.
17. Blumenfeld JD,Laragh JH.Renin system analysis: a rational method for the diagnosis and treatment of the individual patient with hypertension.Am J Hypertens. 1998;11:894-896.
18. Egan BM,Basile JN,Rehman SU,et al.Plasma renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial.Am J Hypertens. 2009;22:792-801.
19. Sealey JE,Laragh JH.Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness.Am J Hypertens. 2007;20:587-597.
20. Hasler C,Nussberger J,Mailard M,et al.Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor.Clin Pharmacol Ther. 2005;78:501-507.
21. Sealey JE,Parra D,Rosenstein R,Laragh JH."Effective" plasma renin activity: a derived measure for assessing residual plasma renin activity in patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.Hypertension. 2010;55:e16-e17.
22. Rosendorff C,Black HR,Cannon CP,et al.Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association council for high blood pressure research and the councils on clinical cardiology and epidemiology and prevention.Circulation. 2007;115:2761-2788.
23. US Food and Drug Administration. FDA safety communication: New warning and contraindication for new blood pressure medicines containing aliskiren (Tekturna). http://www.fda.gov/drugs/drugsafety/ucm300889.htm. Accessed April 20, 2012.
24. Parving HH,Brenner BM,McMurray JJ,et al.Cardiorenal end points in a trial of aliskiren for type 2 diabetes.N Engl J Med. 2012;367:2204-2213.
25. Cushman WC,Evans GW,Byington RP,et al.Effects of intensive blood-pressure control in type 2 diabetes mellitus.N Engl J Med. 2010;362:1575-1585.
26. Laragh JH,Sealey JE.The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure.Am J Hypertens. 2011;24:1164-1180.
27. Healthcare Blue Book. Renin activity, plasma. http://www.healthcarebluebook.com/page_Results.aspx?id=723&dataset=lab&g=Renin%20Activity%2C%20Plasma. Accessed May 8, 2013.
28. Centres for Medicare and Medicaid Services. Clinical laboratory fee schedule. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/clinlab.html. Accessed May 8, 2013.